TABLE 1.

Demographic and clinical features of patients enrolled in the study

	Prob. of functional HBV‐specific CD8+ cell response a
	<0.5 (n = 28)	≥0.5 (n = 13)	p value	All (n = 41)
Age (years)	46 (39–56)	50 (42–53)	N.S. b	46 (41–56)
Male sex (N/%)	14/50	8/61	N.S. b	22/54
Mediterranean origin (N/%)	28/100	13/100	N.S. b	41/100
Spain	14/50	10/77		24/59
Romania	14/50	3/23		17/41
Pre‐treatment status
ALT (IU/ml)	63 (46–83)	62 (58–68)	N.S. c	63 (47–74)
HBV DNA (IU/ml) [log scale]	5.7 (4.7–6.6)	4.6 (4.4–6.2)	N.S. c	5.4 (4,6–6.5)
Liver fibrosis (N/%)
F0–F1	15/53	8/63		23/56
F2–F3	13/47	5/37	N.S. b	18/44
NUC treatment duration (years)	5.1 (1.5–6.4)	9 (6.6–13.7)	<0.001 c	6.3 (3.7–8.7)
Age at NUC treatment start (years)	43.7 (35–48)	37.0 (34–44)	N.S. c	41.7 (34–47)
NUC type (N/%)
Tenofovir	23/82	9/70	N.S. b	32/80
Entecavir	4/14	0/0		4/10
Lam. → Adef. → Tenofovir	0/0	3/23		3/7
Lam. → Tenofovir	1/3	1/7		2/5
Status at study recruitment
ALT (IU/ml)	26 (21–31)	23 (18–33)	N.S. c	25 (20–31)
HBV DNA (IU/ml) (log scale)	0 (0–1.5)	0 (0–0)	0.003 c	0 (0–1.3)
HBsAg (IU/ml) (log scale)	3.7 (3.2–4.1)	2.4 (0.6–3.4)	0.001 c	3.5 (2.6–4)

Note: Data are expressed as frequency distribution for categorical variables and as median plus quartiles one and three (Q1–Q3) for quantitative variables.

Abbreviations: Adef., adefovir; Lam, lamivudine; N.A., non‐applicable; NUC, nucleos(t)ide analogue; N.S., non‐significant; Prob, probability.

^a Probability is calculated according to the predictive logistic regression model developed in the study.

^b Chi‐square test.

^c Mann–Whitney U test.